PKR-IN-2

Cat. No.:	HY-19702
CAS No.:	1628428-01-2
Molecular Formula:	$C_{24}H_{28}N_4O_4S$
Molecular Weight:	468.57
Target:	Others
Pathway:	Others

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (106.71 mM; Need ultrasonic)

Preparing Stock Solutions

Mass / Solvent / Concentration	1 mg	5 mg	10 mg
1 mM	2.1342 mL	10.6708 mL	21.3415 mL
5 mM	0.4268 mL	2.1342 mL	4.2683 mL
10 mM	0.2134 mL	1.0671 mL	2.1342 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: **10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline**
   Solubility: ≥ 2.5 mg/mL (5.34 mM); Clear solution
2. Add each solvent one by one: **10% DMSO >> 90% (20% SBE-β-CD in saline)**
   Solubility: ≥ 2.5 mg/mL (5.34 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PKR-IN-2 is a pyruvate kinase (PKR) activator, extracted from patent WO2014139144A1, compound 160, has an IC50 of □100 nM for. PKR (R510Q), PKR (R532W), PKR (WT), and PKR (WT Cell Based).IC50 value: □100 nM (AC50)Target: PKR

REFERENCES

[1]. Popovici-Muller, et al. Preparation of N-(piperidinecarbonylphenyl) sulfonamide compounds as pyruvate kinase modulators. From PCT Int. Appl. (2014), WO2014139144A1 20140918.

[2]. Cianchetta Giovanni, et al. Preparation of aroylpiperidines, particularly arysulfonylamino and heteroarylsulfonylamino substituted, as pyruvate kinase PKM2 modulators useful in the treatment of cancer and compositions containing them. From PCT Int. Appl.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA